Sygnature Discovery - enabling success in drug discovery
Sygnature Discovery (www.sygnaturediscovery.com ) is a leading independent provider of integrated drug discovery resource and expertise. Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).
We add considerable value to our clients' research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes. Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins). We can also provide pre-clinical experimental services support through our sister company RenaSci.
Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships. We have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.
In summary, Sygnature Discovery offers:
• Target validation
• Hit identification
• Hit-to-lead
• Lead optimisation
• Integrated drug discovery programmes
• Medicinal chemistry
• In vitro biology (including biophysics and live cell imaging)
• Computational chemistry
• DMPK
• Protein crystallography
Sygnature Discovery (www.sygnaturediscovery.com ) is a leading independent provider of integrated drug discovery resource and expertise. Since 2011, 33 compounds discovered by Sygnature for clients have entered pre-clinical development and so far 17 of these have progressed to clinical trials (Phases I, II and III).
We add considerable value to our clients' research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit-to-lead, lead optimisation and drug discovery programmes. Sygnature's capabilities include medicinal chemistry, in vitro biology, computational chemistry and informatics, DMPK, and protein crystallography (via affiliate company Peak Proteins). We can also provide pre-clinical experimental services support through our sister company RenaSci.
Sygnature Discovery operates a business whose primary focus is value creation for our clients, through the application of integrated drug discovery know-how and close working relationships. We have built a team of over 400 staff including pharmaceutical industry-experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.
In summary, Sygnature Discovery offers:
• Target validation
• Hit identification
• Hit-to-lead
• Lead optimisation
• Integrated drug discovery programmes
• Medicinal chemistry
• In vitro biology (including biophysics and live cell imaging)
• Computational chemistry
• DMPK
• Protein crystallography
Location: United Kingdom, England, Nottingham
Employees: 201-500
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | BioCity | biocity.co... |
Mentions in press and media 7
| Date | Title | Description |
| 18.04.2023 | Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration | - 'Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening SEOUL, South Korea and NOTTINGHAM, England, ... |
| 18.03.2022 | Sygnature Discovery Limited R & D status and future prospects of small molecule drugs | Sygnature Discovery Limited R & D status and future prospects of small molecule drugs High film permeability, attractiveness of new compounds similar to natural products …………………………………………………………………………………………… 20 Research system that leads ... |
| 09.02.2021 | Sygnature wins Bionow Company of the Year | Sygnature Discovery, a leading provider of outsourced drug discovery services, has been named Company of the Year at the Bionow Annual Awards 2020. The goal of these awards is to highlight the outstanding success and achievements of those w... |
| 11.09.2020 | GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 Therapeutics | Vijay Reddy → Vijay Reddy was seeking a return to the US when he left his role as CMO at London-based Autolus this summer. Philadelphia is that landing spot, as the T cell immunotherapy player Tmunity has put him in charge... |
| 26.06.2020 | Inovio adds two to the leadership team; Adrian Woolfson is out at Sangamo | → Entrenched in a legal battle with their manufacturer that’s evidently blocking them from making their Covid-19 vaccine candidate, Inovio is making some leadership changes. Gene Kim will be president of Inovio Asia, w... |
| 12.09.2019 | Bayer trims 2 top execs, shrinks management board; SpringWorks boosts size of IPO | → After welcoming J&J dealmaker Marianne De Backer to their team as BD chief a little more than a week ago, Bayer announced that it will be reducing the size of the company’s board of management. Hartmut Klusik and Kem... |
| 15.02.2019 | J&J R&D vet Peter Tummino joins the Big Pharma exodus, leaping to Nimbus as CSO; Cadent taps Jodie Morrison for CEO | → After spending the last 16 years as a researcher in Big Pharma, Peter Tummino is going biotech. Peter Tummino Nimbus reports that Tummino is joining the company as its new CSO after his last stint at J&J, where he w... |